Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647366 | 0.83 | RIPK1 (0.41) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL455119 | 0.80 | HTR2A (0.44) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3458357 | 0.80 | RIPK1 (0.42) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL28026250 | 0.80 | RIPK1 (0.42) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL806099 | 0.80 | RIPK1 (0.39) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL438764 | 0.80 | HTR2A (0.44) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL10182854 | 0.78 | RIPK1 (0.39) | RIPK1DPP4FAPDPP8DPP9 | |
| SCHEMBL489929 | 0.76 | RIPK1 (0.41) | RIPK1CES2CES1 | |
| SCHEMBL24973732 | 0.76 | IDO1 (0.46) | RIPK1DPP4DPP7TRPA1 | |
| SCHEMBL439802 | 0.72 | DPP4 (0.39) | DPP4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | RIPK1 668/4885DPP4 2274/4885ALOX15 3145/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | RIPK1 668/4885DPP4 2274/4885ALOX15 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.